Clincosm LogoSign in Get a demo

PRECIOUS: Management of Newly Diagnosed and Uncontrolled Hypertension With Fixed-Dose Combination of Perindopril/Amlodipine and Perindopril/Indapamide/Amlodipine

Sponsor
KRKA (Industry)
Overall Status
Completed
CT.gov ID
NCT03738761
Collaborator
Clinres Farmacija d.o.o. (Industry), University Medical Centre Ljubljana (Other)
471
Enrollment
34
Locations
2
Arms
19.4
Actual Duration (Months)
13.9
Patients Per Site
0.7
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

PRECIOUS Study aims to evaluate the efficacy and safety of therapy with fixed-dose combination (FDC) of perindopril/amlodipine (Amlessa®) and FDC of perindopril/indapamide/amlodipine (Co-Amlessa®) on blood pressure reduction in both previously untreated patients and patients with previous antihypertensive therapy.

Adult patients with AH who are treatment-naïve with systolic blood pressure (SBP) from 150 mmHg or higher AND/OR diastolic blood pressure (DBP) from 95 mmHg or higher (SBP ≥ 150 mm AND/OR DBP ≥ 90 mmHg for patients with type 2 diabetes mellitus ) and uncontrolled patients on mono, dual or triple antihypertensive therapy with systolic blood pressure (SBP) from 140 mmHg or higher AND/OR diastolic blood pressure (DBP) from 90 mmHg or higher (SBP ≥ 140 AND/OR DBP ≥ 85 mmHg for patients with type 2 diabetes mellitus) will be invited to participate in this study.

During 16-week trial, seven study visits are planned. At first study visit physical examination, medical history, BP measurement, electrocardiogram (ECG), laboratory analysis and of Ambulatory Blood Pressure Measurement (ABPM) will be performed. Based on their previous antihypertensive therapy, patients will receive to treatment with either Amlessa® or Co-Amlessa® for the duration of 16 weeks and blood pressure measurements, laboratory investigations and patient interviews will be performed at study follow-up visits to assess the treatment efficacy (proportion of patients reaching normal office blood pressure after 16 weeks of treatment) and safety.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

PRECIOUS study is an interventional, open-label, prospective, international, multi-centre, Phase IV clinical trial (Phase III for countries without marketing authorisation for Co-Amlessa®).

The purpose of the study is to establish the efficacy and safety of fixed-dose combination (FDC) of perindopril/amlodipine (Amlessa®) and FDC of perindopril/indapamide/amlodipine (Co-Amlessa®) in wide populations of newly diagnosed and uncontrolled patients with arterial hypertension (AH) with special focus on effective continuous 24-hour blood pressure (BP) control. The purpose is also to establish the correlation between 24-hour central and peripheral BP.

Perindopril, indapamide and amlodipine are well known and extensively studied antihypertensive monotherapies. Clinical data and safety analyses provided are substantial body of evidence that perindopril, indapamide and amlodipine, which have been used for more than 15 years, are safe and well tolerated drugs. Perindopril, indapamide and amlodipine have complementary actions in reducing BP. Combining perindopril and amlodipine or perindopril, indapamide and amlodipine could improve adherence in uncontrolled hypertensive patients. Namely the combinations would reduce the number of tablets to be taken by patient and thus simplify the treatment regimen and are therefore expected to facilitate long-term adherence to antihypertensive therapy, which justifies their use. Both combinations could also improve safety profile which would be beneficial from the tolerability point of view. Namely, when calcium channel blockers (CCB) and angiotensin converting enzyme inhibitors (ACEI) are used in combination, there is a potential for lower incidence of peripheral oedema caused by CCB. Similarly, the incidence of ACEI-associated cough is attenuated by CCBs, including amlodipine.

This study aims evaluate the effect of therapy with Amlessa® and Co-Amlessa® on the blood pressure reduction in patients with essential arterial hypertension (AH) who are naïve with systolic blood pressure (SBP) from 150 mmHg or higher AND/OR diastolic blood pressure (DBP) from 95 mmHg or higher, (SBP ≥ 150 AND/OR DBP ≥ 90 mmHg for patients with type 2 diabetes mellitus) and in uncontrolled patients on mono, dual or triple antihypertensive with SBP from 140 mmHg or higher AND/OR DBP from 90 mmHg or higher (SBP ≥ 140 AND/OR DBP ≥ 85 mmHg for patients with type 2 diabetes mellitus). An objective of this trial is also to evaluate the safety of therapy with Amlessa® and Co-Amlessa® according to the frequency and severity of AR in patients with essential AH. Overall 510 patients are planned to conclude the assessment and to be analysed. In per-protocol analysis 450 patients are expected. In order to allow for the estimated drop-out rate, up to 570 patients are expected to be screened.

All patients start with an initial screening which is performed one day before visit 1 to verify eligibility. After inform consent signature and before therapy is allocated complete medical history, physical examination with measurements of heart rate (HR), body weight and height, lipid measurements and laboratory analysis including pregnancy test, BP, ambulatory blood pressure measurement (ABPM) and electrocardiogram (ECG) are performed. Patients take the last doses of previous AH therapy on the day of the screening visit. At Visit 1 (day 0) the data from ABPM device is collected (average BP, central BP, HR, pulse wave velocity [PWV] and Aortic augmentation index). BP and HR measurements are repeated. Based on data gathered from all previous examinations on visit -1 and visit 1 investigator verifies patient's eligibility. Patients will not be randomized to treatment. All eligible patients are assigned to start receiving any of the two study medication (Amlessa® and Co-Amlessa®) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® group. Patient starts taking the study medication on day of the visit 1 (day 0).

The total active treatment duration is 16 weeks, with maximal allowed prolongation of 3 additional days per each of the four treatment periods due to possible unpredicted causes for delay in the follow-up visits. The whole trial treatment schedule was determined on the basis of published pharmacological data for all active substances in study medications. During the active treatment period each patient orally consumes one unit of assigned study medication once daily, at about the same time each day (± 3 hours), preferably in the morning and before a meal.

At visit 2, on day 28 of the treatment period, BP, HR measurements, safety assessing laboratory investigations (serum creatinine, serum potassium, ALT, AST, GammaGT) are repeated. Patient's compliance is assessed and safety assessment is carried out by the interview. After the control of patient status the decision is made to maintain the treatment if sufficient (normal office BP was reached) or to change the treatment in accordance with protocol treatment model. Normal office BP is defined as SBP < 140 mmHg and DBP < 90 mmHg; patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg.

At Visit 3 on day 56 of the active treatment period, BP, HR measurements measurements, lipid measurements and safety assessing laboratory investigations (serum creatinine, serum potassium, ALT, AST, GammaGT) are repeated. Patient's compliance is assessed and safety assessment is carried out by the interview. After the control of patient status the decision is made to maintain the treatment if sufficient (normal office BP was reached) or to change the treatment in accordance with protocol treatment model. Normal office BP is defined as SBP < 140 mmHg and DBP < 90 mmHg; patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg.

At Visit 4 on day 84 of the active treatment period, BP, HR measurements measurements are repeated. Patient's compliance is assessed and safety assessment is carried out by the interview. After the control of patient status the decision is made to maintain the treatment if sufficient (normal office BP was reached) or to change the treatment in accordance with protocol treatment model. Normal office BP is defined as SBP < 140 mmHg and DBP < 90 mmHg; patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg.

At Visit -5 on day 111, ABPM device is installed. Blood samples are taken, to provide the results of laboratory analysis the next day on visit 5 (final visit). At Visit 5 on day 112, the final efficacy and safety evaluation are carried out including patient's adherence. Physical examination with BP, PWV and HR measurements, lipid measurements, laboratory analysis and ABPM are performed. ABPM device is removed on the same day and the data from device is collected (average BP, central BP, HR, PWV and Aortic augmentation index). Completion of all the procedures at Visit 5 determines the end of the patient's involvement in this clinical trial. After this, patient's further antihypertensive regimen is left to the discretion of the investigator.

Once enrolled, patients can be excluded before the protocol defined end of therapy due to patients decision or loss-to-follow-up, patient non-compliance or safety issues as defined in the study protocol. Concomitant therapy with other drugs is avoided in this study, if possible.

The primary efficacy endpoint is the responder rate at final visit. Precisely, this is defined to be the proportion of patients reaching normal blood pressure at Visit 5 (after 16 weeks). Normal office BP is defined as SBP < 140 mmHg and DBP < 90 mmHg; patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg. It will be assessed with the two-sided ("equal-tails") Clopper-Pearson exact 95%-confidence interval for a population proportion.

This trial is going to be conducted in compliance with the approved protocol and in accordance with the principles of Good Clinical Practice (GCP) with its corresponding Directives and Declaration of Helsinki. Data management is carried out by the sponsor according to the data management plan, sponsor's standard operating procedures (SOPs) and GCP. Data to be collected according to the study protocol (and amendments, if any) will be recorded in electronic case report forms (eCRF).

Study Design

Study Type:
Interventional
Actual Enrollment :
471 participants
Allocation:
Non-Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Treatment is started at Visit 1 with Amlessa® 4mg/5mg (Amlessa® Arm) or Co-Amlessa® 4mg/1,25mg/5mg (Co-Amlessa® Arm) for 4 weeks. At each of the three follow-up visits (at week 4, week 8 and week 12) patient BP is assessed and if normal office blood pressure was achieved, the treatment with the study medication prescribed for the previous treatment period is continued. If normal office blood pressure was not achieved at any of the follow-up visits (week 4, week 8 and week 12), Amlessa® or Co-Amlessa® strength is increased in accordance with the below sequence. Amlessa® Arm Amlessa® 4mg/5mg (initial therapy) - Amlessa® 8mg/5mg - Amlessa® 8mg/10mg - Co-Amlessa® 8mg/2,5mg/10mg Co-Amlessa® Arm Co-Amlessa® 4mg/1,25mg/5mg - Co-Amlessa® 8mg/2,5mg/5mg - Co-Amlessa® 8mg/2,5mg/10mg - end of study no further escalation of study medication dosage Normal office BP is defined as SBP < 140 mmHg and DBP < 90 mmHg; patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg.Treatment is started at Visit 1 with Amlessa® 4mg/5mg (Amlessa® Arm) or Co-Amlessa® 4mg/1,25mg/5mg (Co-Amlessa® Arm) for 4 weeks. At each of the three follow-up visits (at week 4, week 8 and week 12) patient BP is assessed and if normal office blood pressure was achieved, the treatment with the study medication prescribed for the previous treatment period is continued. If normal office blood pressure was not achieved at any of the follow-up visits (week 4, week 8 and week 12), Amlessa® or Co-Amlessa® strength is increased in accordance with the below sequence. Amlessa® Arm Amlessa® 4mg/5mg (initial therapy) - Amlessa® 8mg/5mg - Amlessa® 8mg/10mg - Co-Amlessa® 8mg/2,5mg/10mg Co-Amlessa® Arm Co-Amlessa® 4mg/1,25mg/5mg - Co-Amlessa® 8mg/2,5mg/5mg - Co-Amlessa® 8mg/2,5mg/10mg - end of study no further escalation of study medication dosage Normal office BP is defined as SBP < 140 mmHg and DBP < 90 mmHg; patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Fixed-Dose Combination of Perindopril/Amlodipine (Amlessa®) and Fixed-Dose Combination of Perindopril/Indapamide /Amlodipine (Co-Amlessa®) - Contribution to Management in Newly Diagnosed and Uncontrolled Hypertensive Patients
Actual Study Start Date :
Feb 13, 2018
Actual Primary Completion Date :
Sep 27, 2019
Actual Study Completion Date :
Sep 27, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Amlessa® Arm

Patients allocated to treatment with Amlessa® (starting FDC of perindopril 4mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria.

Drug: Amlessa®
Fixed-dose combination (FDC) of perindopril/amlodipine, tablets. Strengths: 4mg/5 mg, 8mg/5 mg, 8mg/10 mg.

Drug: Co-Amlessa®
Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.
Experimental: Co-Amlessa® Arm

Patients allocated to treatment with Co-Amlessa® (starting FDC perindopril 4mg/indapamide 2,5mg/amlodipine 5mg) according to their previous antihypertensive therapy and as described in the protocol inclusion criteria. Patients on previous perindopril and amlodipine therapy will be automatically assigned to Co-Amlessa® arm.

Drug: Co-Amlessa®
Fixed-dose combination (FDC) of perindopril/indapamide/amlodipine, tablets. Strengths: 4mg/1.25 mg/5 mg, 8mg/2.5 mg/5 mg, 8mg/2.5 mg/10 mg.

Outcome Measures

Primary Outcome Measures

  1. Systolic and diastolic blood pressure at Week 16 [16 weeks]

    Responder rate at end of study (week 16): proportion of patients reaching office normal blood pressure defined as SBP < 140 mmHg and DBP < 90 mmHg (patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg). BP is measured using a validated automated BP-measuring device.

Secondary Outcome Measures

  1. Systolic and diastolic blood pressure at Week 4, Week 8 and Week 12 [12 Weeks]

    Responder rate at first, second and third study follow-up visits (week 4, week 8 and week 12): proportion of patients reaching office normal blood pressure defined as SBP < 140 mmHg and DBP < 90 mmHg (patients with type 2 diabetes mellitus: SBP < 140 mmHg and DBP < 85 mmHg). BP is measured using a validated automated BP-measuring device.

  2. Mean absolute and relative change in Systolic and diastolic blood pressure from baseline to Week 4, Week 8, Week 12 and Week 16 [16 weeks]

    Mean absolute and relative change from baseline in office SBP and DBP after 4, 8, 12 and 16 weeks (Visit 2, 3, 4, 5). BP is measured using a validated automated BP-measuring device.

  3. Average 24-hour blood pressure at Week 16 [16 weeks]

    Proportion of patients reaching normal average 24h SBP and DBP (<130/80 mmHg) at study end (Week 16). Measurements are obtained with Ambulatory Blood Pressure Measuring (ABPM) device.

  4. Average awake time blood pressure at Week 16 [16 weeks]

    Proportion of patients reaching normal average awake time SBP and DBP (<135/85 mmHg) at study end (Week 16). Measurements are obtained with Ambulatory Blood Pressure Measuring (ABPM) device.

  5. Average sleep time blood pressure at Week 16 [16 weeks]

    Proportion of patients reaching normal average sleep time SBP and DBP (<120/70 mmHg) at study end (Week 16). Measurements are obtained with Ambulatory Blood Pressure Measuring (ABPM) device.

  6. Mean absolute and relative change in average 24-hour blood pressure from baseline to Week 16 [16 weeks]

    Mean absolute and relative change from baseline to 16 weeks in average 24-hour SBP and DBP obtained with Ambulatory Blood Pressure Measuring (ABPM) device.

  7. Mean absolute and relative change in average awake time blood pressure from baseline to Week 16 [16 weeks]

    Mean absolute and relative change from baseline to 16 weeks in average awake time SBP and DBP obtained with Ambulatory Blood Pressure Measuring (ABPM) device.

  8. Mean absolute and relative change in average sleep time blood pressure from baseline to Week 16 [16 weeks]

    Mean absolute and relative change from baseline to 16 weeks in average sleep time SBP and DBP obtained with Ambulatory Blood Pressure Measuring (ABPM) device.

  9. Reduction of office SBP of at least 20 mmHg or DBP of at least 10 mmHg from baseline to 16 weeks [16 weeks]

    Proportion of patients reaching a reduction of office SBP by at least 20 mmHg or DBP by at least 10 mmHg from baseline after 16 weeks. BP is measured using a validated automated BP-measuring device.

  10. Central (systolic) blood pressure at Week 16 [16 weeks]

    Proportion of patients with a reduction of central (systolic) blood pressure (obtained by 24-hour ABPM device measurement) below 120 mmHg at end of study (week 16).

  11. Change in Pulse wave velocity (PWV) from baseline to Week 16 [16 weeks]

    Proportion of patients reaching a reduction of PWV (obtained by 24-hour ABPM device measurement) of at least 0,5 m/s from baseline to study end (week 16).

  12. Change in SBP and DBP variability from baseline to Week 16 [16 weeks]

    Proportion of patients reaching a reduction of SBP and DBP variability expressed as reduction of day-night standard deviation (SDdn) of at least 0.5 and that of average real variability (ARV) of at least 0.5 at study end (week 16). Measurements are obtained with ABPM device.

Other Outcome Measures

  1. Change in serum total cholesterol from baseline to end of study (Week 16) [16 weeks]

    Mean absolute and relative change from baseline to week 16 in total serum cholesterol concentration (obtained by laboratory blood test) in patients with concomitant rosuvastatin therapy.

  2. Change in HDL-C from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative change from baseline to week 16 in high-density lipoprotein-cholesterol (HDL-C) serum concentration (obtained by laboratory blood test) in patients with concomitant rosuvastatin therapy.

  3. Change in LDL-C from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative change from baseline to week 16 in low-density lipoprotein-cholesterol (LDL-C) serum concentration (obtained by laboratory blood test) in patients with concomitant rosuvastatin therapy.

  4. Change in triglycerides from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative change from baseline to week 16 in triglycerides serum concentration (obtained by laboratory blood test) in patients with concomitant rosuvastatin therapy.

  5. Change in AST from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative changes above normal limit values from baseline to end of study value (week 16) in serum Aspartate transaminase (AST) concentration obtained by laboratory blood test.

  6. Change in ALT from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative changes above normal limit values from baseline to end of study value (week 16) in serum Alanine transaminase (ALT) concentration obtained by laboratory blood test.

  7. Change in GGT from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative changes above normal limit values from baseline to end of study value (week 16) in serum gamma-glutamyl transferase (GGT) concentration obtained by laboratory blood test.

  8. Change in Serum Creatinine from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative changes above normal limit values from baseline to end of study value (week 16) in Serum Creatinine concentration obtained by laboratory blood test.

  9. Change in Serum Potassium from baseline to end of study (week 16) [16 weeks]

    Mean absolute and relative changes above normal limit values from baseline to end of study value (week 16) in Serum Potassium concentration obtained by laboratory blood test.

  10. Incidence of adverse drug reactions from date of screening until study end (16 weeks) [16 weeks]

    Incidence of adverse drug reactions from date of screening until study end (16 weeks). A number/percentage of patients unable to finish active treatment periods due to clinically significant adverse reaction.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
INCLUSION CRITERIA:

  • Patients with essential arterial hypertension.*

  • Men and women aged ≥ 18 years

  • Written informed consent

  • Ability to adhere to study protocol

Additional inclusion criteria for Amlessa®*

Patients with essential arterial hypertension:

  • Naïve patients with systolic blood pressure (SBP) from 150 mmHg or higher AND/OR diastolic blood pressure (DBP) from 95 mmHg or higher (SBP ≥ 150 AND/OR DBP ≥ 90 mmHg for patients with type 2 diabetes mellitus)

  • Uncontrolled patients on antihypertensive monotherapy with SBP from 140 mmHg or higher AND/OR DBP from 90 mmHg or higher (SBP ≥ 140 AND/OR DBP ≥ 85 mmHg for patients with type 2 diabetes mellitus).

  • Uncontrolled patients on dual antihypertensive therapy (either in monoforms or FDC) with SBP from 140 mmHg or higher AND/OR DBP from 90 mmHg or higher (SBP ≥ 140 AND/OR DBP ≥ 85 mmHg for patients with type 2 diabetes mellitus).

Additional inclusion criteria for Co-Amlessa®*

Patients with essential arterial hypertension (AH):

  • Uncontrolled patients on dual antihypertensive therapy (either in monoforms or FDC, including perindopril+amlodipine combination) with SBP from 140 mmHg or higher AND/OR DBP from 90 mmHg or higher (SBP ≥ 140 AND/OR DBP ≥ 85 mmHg for patients with type 2 diabetes mellitus).

  • Uncontrolled patients on triple antihypertensive therapy (either in monoforms or FDC) with SBP from 140 mmHg or higher AND/OR DBP from 90 mmHg or higher (SBP ≥ 140 AND/OR DBP ≥ 85 mmHg for patients with type 2 diabetes mellitus).

EXCLUSION CRITERIA:

  • History of adverse reactions or hypersensitivity associated with the use of the active substances, or any other components of the Investigational medicinal products (IMPs) used in the trial.

  • Hereditary/idiopathic angioedema.

  • Known secondary AH (e.g. pheochromocytoma, primary aldosteronism, renal artery stenosis).

  • Office measured Systolic blood pressure ≥200 mmHg.

  • Unstable angina pectoris.

  • Acute heart failure and heart failure New York Heart Association (NYHA) Class IV.

  • Antihypertensive drugs used for other indication than AH (e.g. tachyarrhythmia, glaucoma) less than 3 months before the study or in changed dosages less than 3 months before the study.

  • Severe liver impairment OR biliary cirrhosis OR cholestasis OR hepatic encephalopathy.

  • Renal dysfunction - glomerular filtration rate (GFR) <60 ml/min, bilateral renal artery stenosis, renal artery stenosis in a solitary kidney, patients with only 1 kidney, or post-renal transplant patients, dialysis patients.

  • Any of the following clinically relevant laboratory or ECG findings:

  • significant anaemia with haemoglobin less than 100 g/l

  • serum aspartate transaminase (AST) and/or alanine aminotransferase (ALT) and/or alkaline phosphatase (ALP) and/or gamma-glutamyltransferase (GGT) of more than 3 x upper limit of normal (ULN)

  • hyperkalaemia (serum potassium of more than 5 mmol/l)

  • A-V block grade 2 or 3

  • ECG signs of acute ischemia

  • Concurrent therapy with:

  • aliskiren-containing products (in patients with diabetes mellitus or renal impairment)

  • Other antihypertensive drugs or other medications that may cause hypotension: exception are antihypertensive drugs used for other indication than AH (e.g. tachyarrhythmia, glaucoma) introduced more than 3 months before the study or in changed dosages more than 3 months before the study

  • Drugs that may produce an increase in blood pressure: systemic corticosteroids, hormonal medications (chronically used oral contraceptives are allowed), adrenergic receptor agonists, cyclosporine, erythropoietin, migraine medications such as triptans and ergotamines

  • Agents with important interactions with perindopril or to any other ACE inhibitor, to indapamide or to any other sulphonamides, to amlodipine or to dihydropyridine derivatives: lithium, estramustine

  • Agents that may interfere with amlodipine hepatic metabolism (CYP3A4): protease inhibitors, rifampicin, macrolides like erythromycin or clarithromycin, azole antifungals like ketoconazole and itraconazole, Hypericum perforatum.

  • Medications contraindicated in uncontrolled arterial hypertension: anticoagulants, thrombolytics.

  • Bradycardia with heart rate less than 50/min.

  • Female patients who are pregnant, planning to become pregnant.

  • Breastfeeding female patients.

  • Any significant acute condition (severe infection, exacerbation or uncontrolled phase of a chronic disease, major trauma, major surgery) within 30 days prior to screening visit.

  • Pathological clinical states (e.g. malignant diseases, excessive alcohol consumption, drug abuse or drug addiction, psychiatric conditions) or any life-threatening illness.

  • Patients currently participating in another clinical trial.

  • Patient's refusal to participate with the investigator.

  • Normal average 24-hour SBP and DBP obtained by Ambulatory Blood Pressure Measurement (ABPM) device (<130/80 mmHg) at baseline.

  • Severe orthostatic hypotension.

  • Patients to whom β-blocker therapy cannot be discontinued in one day.

  • Previous or current therapy with perindopril and amlodipine and indapamide taken taken concomitantly all together as 3 separate tablets or as a fixed-dose combination.

  • In Amlessa arm patients on previous or current therapy with perindopril and amlodipine taken concomitantly all together as 2 separate tablets or as a fixed-dose combination. (this exclusion criterion does not apply to Co-Amlessa arm).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Unimed medical center Abovyan Armenia
2 Center of Preventive Cardiology Yerevan Armenia
3 Thalassotherapia Opatija, Specijalna bolnica za medicinsku rehabilitaciju, bolesti srca, pluća i reumatizma, Klinika za liječenje, rehabilitaciju i prevenciju bolesti srca i krvnih žila Opatija Croatia
4 KBC Rijeka - Sušak, Klinika za internu medicinu, Zavod za nefrologiju, dijalizu i transplantaciju bubrega RIjeka Croatia
5 KB Merkur, Klinika za unutarnje bolesti, Zavod za kardiologiju Zagreb Croatia
6 KBC Sestre milosrdnice, Klinika za bolesti srca i krvnih žila, Zavod za bolesti krvnih žila Zagreb Croatia
7 KBC Zagreb, Klinika za bolesti srca i krvnih žila Zagreb Croatia
8 KBC Zagreb, Klinika za unutarnje bolesti, Zavod za nefrologiju, arterijsku hipertenziju, dijalizu i transplantaciju Zagreb Croatia
9 Poliklinika za prevenciju kardiovaskularnih bolesti i rehabilitaciju SRČANA Zagreb Croatia
10 Biatros Kft. Biatorbágy Hungary
11 General practitioner office Budapest Hungary
12 AD SANITATEM Bt. Pilisvörösvár Hungary
13 Przychodnia Kardiologiczna w Zespole Przychodni Specjalistycznych DIAB-END-COR Krakow Poland
14 Niepubliczny Zakład Opieki Zdrowotnej Neuromed M.i M. Nastaj Spółka Partnerska Lublin Poland
15 Poradnia Kardiologiczna, Nowodworskie Centrum Medyczne Nowy Dwór Mazowiecki Poland
16 Poradnia Kardiologiczna Samodzielnego Publicznego Zespołu Zakładów Opieki Zdrowotnej im. Marszałka Józefa Piłsudskiego w Płońsku Płońsk Poland
17 Poradnia Kardiologiczna w Niepublicznym Zakładzie Opieki Zdrowotnej Euro-Klinika Sp. z o.o. w Siemianowicach Śląskich Siemianowice Śląskie Poland
18 Poradnia internistyczno-kardiologiczna w Niepublicznym Zakładzie Opieki Zdrowotnej AURUM Warsaw Poland
19 Poradnia Kardiologiczna w Przychodni Rejonowej - Specjalistycznej (III) Samodzielnego Zespołu Publicznych Zakładów Lecznictwa Otwartego Warszawa - Ochota Warsaw Poland
20 Przychodnia ACTIV-MED. Warsaw Poland
21 Federal State Budgetary Scientific Institution "Scientific Research Institute of Complex Problems of Cardiovascular Diseases" Kemerovo Russian Federation
22 Federal State budget organization National medical research center of cardiology of the Ministry of healthcare of the Russian Federation Moscow Russian Federation
23 State Budgetary Institution of Healthcare of Moscow "City Clinical Hospital № 29 named after N.E. Bauman of Department of Healthcare of Moscow city" (SBIH "CCH № 29 Bauman") Moscow Russian Federation
24 Federal State Budgetary Institution "V.A. Almazov National Medical Research Center" of the Ministry of Health of the Russian Federation (V.A. Almazov NMRC) Saint Petersburg Russian Federation
25 Federal State Budgetary Educational Institution Higher Education "Volgograd State Medical University" of the Ministry of Healthcare of the Russian Federation (FSBEI HE VolgSMU MOH Russia) Volgograd Russian Federation
26 Klinički centar Srbije Belgrade Serbia
27 KBC Dragiša Mišović Belgrad Serbia
28 Klinički centar Niš Niš Serbia
29 Inštitut za kardiovaskularne bolesti Vojvodine Sremska Kamenica Serbia
30 Univerzitetna klinika za pljučne bolezni in alergijo Golnik Golnik Slovenia
31 Splošna bolnišnica Jesenice Jesenice Slovenia
32 Ordinacija interne medicine Verboten Kopriva Renata Litija Slovenia
33 MC Medicor, d. d. Ljubljana Slovenia
34 Intermed, d. o. o. Maribor Slovenia

Sponsors and Collaborators

  • KRKA
  • Clinres Farmacija d.o.o.
  • University Medical Centre Ljubljana

Investigators

  • Principal Investigator: Jana Brguljan Hitij, University Medical Centre Ljubljana Hospital dr. Peter Držaj

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
KRKA
ClinicalTrials.gov Identifier:
NCT03738761
Other Study ID Numbers:
  • KCT 06/2017
  • 2017-001596-23
First Posted:
Nov 13, 2018
Last Update Posted:
Sep 2, 2020
Last Verified:
Sep 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by KRKA
Hypertension
Blood pressure control
Fixed-dose combination antihypertensives
Ambulatory blood pressure monitoring
Additional relevant MeSH terms:
Hypertension

Study Results

No Results Posted as of Sep 2, 2020